These assumptions were used in lieu of clinical data informing changes in HbA1c and BMI on initiation of SGLT-2 inhibitor or basal insulin therapy in populations previously receiving metformin and GLP-1 receptor agonist therapy, and this remains the key limitation in modelling more complex treatment algorithms for type 2 diabetes. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.